Clinical Trials

Janssen’s Erleada shown to reduce PSA progression by 94% in nmCRPC patients

Janssen Pharmaceutical's androgen receptor inhibitor Erleada (apalutamide) succeeded in a phase 3 trial by significantly cutting down the risk of prostate specific antigen (PSA) progression in patients having non-metastatic castration-resistant prostate cancer (nmCRPC).

Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial

Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib

Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.

Merck to invest $125m in Moderna Therapeutics

Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.

Karyopharm’s multiple myeloma drug Selinexor succeeds in phase 2b study

Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma.

Allergan’s ubrogepant migraine drug succeeds in second phase 3 trial

Allergan’s migraine drug ubrogepant has succeeded in a phase 3 trial by meeting its co-primary endpoints for a 50mg dose.

Vertex launches phase 3 trials of VX-445/Tezacaftor/Ivacaftor combo in cystic fibrosis

Vertex Pharmaceuticals has initiated two phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).

Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study

Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.

Boehringer Ingelheim, Lilly, University of Oxford to study empagliflozin in chronic kidney disease

Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.